Zaven Kaprielian is an experienced neuroscientist with a focus on ALS.

Zaven brings more than thirty years of industry and academic experience including corporate leadership and research and development. Zaven was Chief Science Officer at Remix, leading the scientific development of their REMaster platform to bring new medicines to patients in need by reprogramming RNA processing.

Prior to Remix, Zaven was Chief Operating Officer and Project Chief Scientific Officer of Dementia Discovery Fund (DDF) U.S. Discovery, and a Venture Partner with the DDF. Before that, he was Director of Neuroscience Research at Amgen, where he managed several teams and programs tasked with identifying novel therapeutics for neuropathic pain and neurodegenerative disorders. Zaven previously held numerous academic appointments in neuroscience at Albert Einstein College of Medicine, where he directed a research group focused on the molecular mechanisms that control axon guidance and dendrite branching in the developing central nervous system.

Zaven holds a B.S. in Aerospace Engineering and an M.A. in Physics from Boston University. He holds a Ph.D. in Biophysics from The Johns Hopkins University and completed his postdoctoral research in developmental neuroscience at the California Institute of Technology.